24/7 Market News Snapshot 24 September, 2024 – Kairos Pharma, Ltd. (NYSE:KAPA)
DENVER, Colo., 24 September, 2024 (247marketnews.com) – (NYSE:KAPA) are discussed in this article.
Shares of Kairos Pharma, Ltd. (KAPA) have seen a remarkable surge, rising by 45.20% to reach $2.90 today, following an opening price of $2.07. This significant increase has drawn considerable attention from investors, as evidenced by a trading volume of 852.31K shares. Such a vibrant upward momentum reflects a strong and positive market sentiment, indicating the potential for continued growth in the company’s stock.
In an exciting development, Kairos Pharma has announced a strategic partnership with PreCheck Health Services Inc., a frontrunner in genetic sequencing and diagnostics. This collaboration aims to enhance the precision of patient screening and monitoring for ENV105, an innovative cancer treatment targeting prostate and lung cancers. As the company advances through Phase 1 and Phase 2 clinical trials, this alliance is poised to transform personalized cancer care.
Utilizing PreCheck’s proprietary SolidTumorCheck+ platform, the partners will analyze biopsy tissues and circulating tumor cells from participants in the ongoing trials. This collaboration is designed to confirm existing biomarkers and identify new ones, enabling a more tailored treatment approach for patients, particularly for those who have shown resistance to existing therapies. A key objective is to develop a companion diagnostic tool that will seek FDA approval, refining patient selection for future trials.
Dr. Neil Bhowmick, Chief Scientific Officer of Kairos Pharma, highlighted the significance of this partnership, stating it will enhance their ability to identify suitable candidates for ENV105, ultimately improving patient outcomes. This collaboration underscores Kairos Pharma’s commitment to advancing cancer treatments and offering personalized solutions, promising a brighter future for patients facing resistant forms of prostate and lung cancers. As developments unfold, this partnership holds the potential to redefine treatment paradigms in the fight against cancer.